BerGenBio to Present at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Bergen, Norway, August 30th, 2018 – BerGenBio ASA (OSE:BGBIO), announces that Richard Godfrey, CEO of BerGenBio, is scheduled to present an overview of the Company's business and ongoing phase II clinical development programme with its first-in-class selective AXL inhibitor bemcentinib at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on September 5th 2018 at 9:35 AM (Eastern Time).The presentation will be webcast live. To access presentation slides and webcast, please visit www.bergenbio.com/investors/presentations/. The webcast